UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aldeyra Therapeutics (ALDX) Prices 5.25M Share Common Offering at $13.75/Sh
September 28, 2018 5:34 AM EDTAldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering... More
Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor Fitzgerald
September 26, 2018 9:33 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.
Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More
Aldeyra Therapeutics (ALDX) Reports Positive Results from Phase 2b Dry Eye Disease Clinical Trial
September 26, 2018 7:01 AM EDTAldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease.
"The early onset and broad activity observed in the Phase 2b clinical trial suggests that reproxalap could be an... More
